ATE492537T1 - Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin - Google Patents

Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin

Info

Publication number
ATE492537T1
ATE492537T1 AT06794584T AT06794584T ATE492537T1 AT E492537 T1 ATE492537 T1 AT E492537T1 AT 06794584 T AT06794584 T AT 06794584T AT 06794584 T AT06794584 T AT 06794584T AT E492537 T1 ATE492537 T1 AT E492537T1
Authority
AT
Austria
Prior art keywords
medicine
compounds
receptor activity
receptor
activity
Prior art date
Application number
AT06794584T
Other languages
German (de)
English (en)
Inventor
Brian Budzik
David Cooper
Ian FORBES
Vincenzo Garzya
Jian Jin
Dongchuan Shi
Paul Smith
Graham Walker
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE492537T1 publication Critical patent/ATE492537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT06794584T 2005-09-30 2006-09-27 Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin ATE492537T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds
PCT/GB2006/003590 WO2007036715A2 (en) 2005-09-30 2006-09-27 Compounds which have activity at m1 receptor and their uses in medicine

Publications (1)

Publication Number Publication Date
ATE492537T1 true ATE492537T1 (de) 2011-01-15

Family

ID=37598231

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06794584T ATE492537T1 (de) 2005-09-30 2006-09-27 Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin

Country Status (24)

Country Link
US (2) US8283364B2 (https=)
EP (1) EP1943230B1 (https=)
JP (1) JP5209480B2 (https=)
KR (2) KR101374458B1 (https=)
CN (1) CN101321736B (https=)
AR (1) AR056103A1 (https=)
AT (1) ATE492537T1 (https=)
AU (1) AU2006296369B2 (https=)
BR (1) BRPI0616609A2 (https=)
CA (1) CA2624504C (https=)
CR (1) CR9904A (https=)
DE (1) DE602006019119D1 (https=)
EA (1) EA016286B1 (https=)
IL (1) IL190219A (https=)
JO (1) JO2634B1 (https=)
MA (1) MA29849B1 (https=)
MY (1) MY148504A (https=)
NO (1) NO20081945L (https=)
NZ (1) NZ566508A (https=)
PE (1) PE20070490A1 (https=)
TW (1) TWI389905B (https=)
UA (1) UA101299C2 (https=)
WO (1) WO2007036715A2 (https=)
ZA (1) ZA200802167B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0616609A2 (pt) 2005-09-30 2011-06-28 Glaxo Group Ltd compostos que têm atividade no receptor m1, composição farmacêutica contendo tais compostos, processo para preparação dos mesmos, bem como seus usos em medicina
WO2007036711A1 (en) 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
EP1960389B1 (en) * 2005-09-30 2012-08-15 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
US20170333407A1 (en) * 2014-11-03 2017-11-23 William Beaumont Hospital Method for treating underactive bladder syndrome
RS61688B1 (sr) 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
US10604484B2 (en) * 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
ATE275141T1 (de) 1999-10-13 2004-09-15 Banyu Pharma Co Ltd Substituierte imidazolin-derivate
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
US20020019395A1 (en) 2000-02-01 2002-02-14 Bing-Yan Zhu Indalone and benzimidazolone inhibitors of factor Xa
US6872733B2 (en) 2001-04-18 2005-03-29 Euro-Celtique S.A. Benzimidazolone compounds
JPWO2002085890A1 (ja) 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
ATE516030T1 (de) 2001-10-02 2011-07-15 Acadia Pharm Inc Benzimidazolidinon-derivate als muscarinische mittel
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
JP4056977B2 (ja) 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
JP2005532361A (ja) 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
BR0317230A (pt) 2002-12-13 2005-10-25 Smithkline Beecham Corp Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
WO2005009996A1 (en) 2003-07-23 2005-02-03 Wyeth Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands
KR100738784B1 (ko) 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
MX2007005290A (es) 2004-11-02 2007-07-09 Pfizer Derivados de sulfonilbencimidazol.
US7300947B2 (en) 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
WO2007036711A1 (en) 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
EP1960389B1 (en) 2005-09-30 2012-08-15 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
BRPI0616609A2 (pt) 2005-09-30 2011-06-28 Glaxo Group Ltd compostos que têm atividade no receptor m1, composição farmacêutica contendo tais compostos, processo para preparação dos mesmos, bem como seus usos em medicina
WO2008029377A2 (en) 2006-09-08 2008-03-13 The Gillette Company Toothbrush with multiple bristle states
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
AU2006296369B2 (en) 2012-12-20
WO2007036715A2 (en) 2007-04-05
US8283364B2 (en) 2012-10-09
DE602006019119D1 (de) 2011-02-03
PE20070490A1 (es) 2007-05-30
US20080058378A1 (en) 2008-03-06
JP5209480B2 (ja) 2013-06-12
EA016286B1 (ru) 2012-03-30
EA200801001A1 (ru) 2008-08-29
KR20130091791A (ko) 2013-08-19
IL190219A (en) 2012-10-31
KR20080049090A (ko) 2008-06-03
WO2007036715A3 (en) 2007-05-18
AU2006296369A1 (en) 2007-04-05
US20080255195A1 (en) 2008-10-16
CN101321736B (zh) 2012-04-04
KR101374458B1 (ko) 2014-03-17
NZ566508A (en) 2011-07-29
TW200806657A (en) 2008-02-01
MA29849B1 (fr) 2008-10-03
MY148504A (en) 2013-04-30
UA101299C2 (uk) 2013-03-25
NO20081945L (no) 2008-06-04
IL190219A0 (en) 2008-11-03
CA2624504A1 (en) 2007-04-05
JP2009512635A (ja) 2009-03-26
CA2624504C (en) 2014-07-08
JO2634B1 (en) 2012-06-17
EP1943230A2 (en) 2008-07-16
TWI389905B (zh) 2013-03-21
CN101321736A (zh) 2008-12-10
US8481566B2 (en) 2013-07-09
BRPI0616609A2 (pt) 2011-06-28
CR9904A (es) 2008-07-29
AR056103A1 (es) 2007-09-19
ZA200802167B (en) 2009-08-26
EP1943230B1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
ATE492537T1 (de) Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
DE602005023681D1 (de) Infrarotabsorbierende Verbindungen und deren Verwendung in Bildaufzeichnungselementen
ATE468326T1 (de) Verbindungen zur verstärkung der glutamatrezeptorwirkung und deren verwendung in der medizin
ATE473229T1 (de) Tricyclische verbindungen und deren verwendung als mglur1-antagonisten
DE602006017566D1 (de) Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE530553T1 (de) Zytotoxische mittel mit neuen tomamycin-derivaten und ihre therapeutische verwendung
DE602006019923D1 (de) Sensor und Aufzeichnungsgerät mit demselben
DE602007012308D1 (de) Bicyclische pyrimidinone und deren verwendung
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
DE602006007049D1 (de) Heizelement und Heizvorrichtung mit Heizelementen
ATE440093T1 (de) 1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide
DE602005022169D1 (de) Polymerisierbare verbindungen und verwendung davon
DE602005007546D1 (de) Kombiniertes Screening-System mit Röntgenstrahlendiffraktion und Ramanspektroskopie
DE602004003030D1 (de) Infrarot-absorbierende verbindungen und ihre verwendung in bebilderbaren elementen
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE602007006540D1 (de) Cyclopropancarboxylate und deren verwendung als pestizide
ATE442366T1 (de) Oxazolidinonderivate und ihre verwendung als antibiotika
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE602005022211D1 (de) Sieb und sichter mit siebbruchdetektor
DE602006009296D1 (de) Oligopeptide und ihre verwendung
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EP1912921A4 (en) TETRAAZAPORPHYRIN COMPOUNDS AND USES THEREOF
ATE531259T1 (de) 2-alkyl-cycloalk(en)yl-carboxamide und ihre verwendung als fungizide
ATE399767T1 (de) 1-phenyl- und 1-pyridylpyrazolderivate und deren verwendung als pestizide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties